Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03972488

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET — NETTER-2  

Gastro-enteropancreatic Neuroendocrine Tumor Clinical Trial

Official title:
A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

Clinical Trial Summary

The aim of NETTER-2 is to determine if Lutathera in combination with long-acting octreotide prolongs PFS in GEP-NET patients with high proliferation rate tumors (G2 and G3), when given as a first line treatment compared to treatment with high dose (60 mg) long-acting octreotide. Somatostatin analog (SSA) naive patients are eligible, as well as patients previously treated with SSAs in the absence of progression.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03972488
Study type Interventional
Source Advanced Accelerator Applications
Contact
Status Active, not recruiting
Phase Phase 3
Start date January 22, 2020
Completion date October 29, 2027
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04614766 - A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors Phase 1/Phase 2
Completed NCT03220217 - To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET) Phase 2
Active, not recruiting NCT05050942 - A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET Phase 3
Recruiting NCT03475953 - A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06253897 - A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly
Recruiting NCT03863106 - The Lyon Real World Evidence in Metastatic NeuroEndocrine Tumours
Terminated NCT03042780 - FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas Phase 2
Active, not recruiting NCT03600233 - Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors Phase 2
Completed NCT01423734 - The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases
Withdrawn NCT02779257 - Pasireotide Treatment for Neuroendocrine Tumor Phase 4